'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease
1997

Hepatoma-specific Alpha-fetoprotein for Early Diagnosis of Liver Cancer

Sample size: 582 publication Evidence: moderate

Author Information

Author(s): PJ Johnson, N Leung, P Cheng, C Welby, WT Leung, WY Lau, S Yu, S Ho

Primary Institution: The Chinese University of Hong Kong, Prince of Wales Hospital

Hypothesis

Can the 'hepatoma-specific' alpha-fetoprotein test improve early diagnosis of malignant changes in patients with chronic liver disease?

Conclusion

The 'hepatoma-specific' alpha-fetoprotein test significantly increases the positive predictive value for diagnosing hepatocellular carcinoma.

Supporting Evidence

  • 19 out of 26 patients with the 'hepatoma-specific' band developed HCC during the study.
  • The positive predictive value of the 'hepatoma-specific' AFP test was 73.1%, compared to 41.5% for total AFP.
  • Ultrasound detected tumors at a median of 3.6 months after the AFP test was positive.

Takeaway

Doctors can use a special blood test to find liver cancer earlier in patients with liver disease, which can help save lives.

Methodology

The study analyzed serum alpha-fetoprotein levels in patients with chronic liver disease and followed them for up to 18 months to diagnose hepatocellular carcinoma.

Potential Biases

The results may not be generalizable due to the specific patient population and the study's design.

Limitations

The study did not assess the impact of the test on patient outcomes or the potential for false positives.

Participant Demographics

91% had hepatitis B virus-related liver disease; less than 10% had alcoholic liver disease.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication